Famed rock climber Alex Honnold masterfully ascended one of the world’s tallest skyscrapers without a rope. “Sick,” he said, standing atop Taipei 101 with a panoramic view of Taiwan’s capital after ...

Professional climber Alex Honnald's live-on-Netflix climb of Taipei 101, one of the world's tallest skyscrapers, has been rescheduled due to weather, Netflix announced Friday night. The streaming ...

On Friday, Alex Honnold—a world-renowned climber and one of Earth’s most fascinatingly fearless people—is scheduled to climb Taipei 101, the 101-story skyscraper that’s one of the world’s tallest ...

BOSTON - Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing molecular glue degrader-based medicines, announced Thursday the pricing of an underwritten ...

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based ...

Shares of Monte Rosa Therapeutics, Inc. (GLUE) surged after the company reported positive interim phase 1 results of MRT-8102, its wholly owned NEK7 molecular glue degrader. We saw significant ...

Investing.com - Monte Rosa Therapeutics (NASDAQ:GLUE) received a reiterated Buy rating from TD Cowen on Wednesday following the company’s presentation of Phase 1 data for its NEK7 degrader. The stock, ...

BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based ...

For over 5 years, Arthur has been professionally covering video games, writing guides and walkthroughs. His passion for video games began at age 10 in 2010 when he first played Gothic, an immersive ...

Hill Climb Racing 3 will feature 3D visuals and real-time PvP action. The title is soft-launching in the UK, Norway, Sweden and Finland on Google Play. HCR 3's soft launch comes nearly nine years ...

The Pacers had reached an agreement with the veteran, but a calf strain will impact Morris's availability for training camp. After previous reporting indicated that the Pacers were nearing a deal with ...

Nearly a year after licensing Monte Rosa Therapeutics’ Phase II-bound autoimmune disease candidate MRT-6160, Novartis has agreed to partner on developing additional molecular glue degraders (MGDs) for ...